CD8A and glioblastoma: In a clinical trial (NCT02669173), metronomic capecitabine combined with bevacizumab (anti-VEGF) treatment demonstrated safety in GBM patients and led to a marked reduction in circulating MDSC levels and an increase in cytotoxic immune infiltration in the TME, including CD8+ effector-memory T cells and NK cells [166].